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Abstract 
Chickens are one of the classic models of vertebrate immunity.  We have been interested 
in the role of the alloantigen chB6 (formerly called BU1) in the development of B cells within 
the bursa and have presented evidence that chB6 can trigger apoptosis.  chB6 is an alloantigen 
and in the original report of its cloning three alleles were reported, chB6.1 in RPL line 6 flocks, 
chB6.2 in RPL line 7, and chB6.3 in Light Sussex birds.  However, no further search for other 
chB6 alleles has been reported.  Using the chicken EST database we have identified four 
potential new alleles of chB6, although some of these EST clones are not full length cDNAs.  
We have resequenced these EST clones to confirm the base sequence and amino acid translation.  
These results suggest greater genetic diversity of the chB6 locus than previously appreciated.  
Furthermore, rt-PCR was used to clone the turkey homologue of chB6. The results presented 
here are the beginnings of a larger study to examine chB6’s role in B cell development that may 
provide novel insights into the evolution of immune related genes in all avian species.  
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Introduction 
Role of the Immune System 
The immune system is an essential component of an organism’s ability to survive, and 
even simple organisms have elements of a defensive immune system. The purpose of the 
immune system is to defend an organism from infection while minimizing damage to the host. 
Vertebrate immune systems are composed of layered defenses with increasing specificity (1). 
 When an infectious agent tries to gain entry into an organism it first must penetrate 
through the physical barriers that serve as the initial defense for the host. These external barriers 
include skin, tears, and mucous membranes. However, if the pathogen overcomes these barriers, 
the body responds via innate immunity mounting an immediate response in a non specific 
manner. Once inside the organism the pathogen travels through local tissue and may encounter 
phagocytes which aid in their removal. Additionally, complement proteins present in the body 
fluids may target infectious agents for attack (1).  
If the pathogen is not removed via the innate immune system adaptive immunity mounts 
a response using highly specific cells known as lymphocytes. There are two classes of 
lymphocytes:  T cells and B cells. The T cells include cytotoxic T cells, sometimes referred to as 
killer cells, and helper T cells that provide stimulatory signals to the B cells (1). B cells are 
essential for pathogen detection and elimination, because they produce antibody molecules 
(Immunoglobulins) that are specific for a single antigen. The diversity of antibody with distinct 
specificities allows for the recognition of a wide variety of antigens. The term antigen refers to 
any substance that can be recognized by the cells of the adaptive immune system (1). The 
antibody molecules are either cell bound, forming a B cell receptor complex, or are secreted by 
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the cell as a soluble form into the circulation (1). The antibodies released bind to antigens and aid 
in their removal. B cells that have participated in active immune responses produce daughter 
cells that are retained in immune tissues, creating a memory bank of previous exposure. This 
increases the ability of our body to detect specific antigens upon subsequent encounter and 
decrease elimination time, thus reducing secondary infections (1).  
Each individual immunoglobulin (Ig) molecule is composed of four basic structural units: 
two heavy chains and two light chains (1). Each light chain consists of a variable region and a 
constant region while the heavy chain contains a variable region and several constant regions (1). 
The variable regions of the heavy and light chains compose the paratope of the antibody which 
forms noncovalent bonds with the small region of the antigen called the epitope (1). 
Recombination of the gene segments encoding the variable region within individual B cells 
means that each cell makes a unique paratope (1). This diversity of paratopes ensures that 
virtually any foreign agent can be detected (1). The gene rearrangements of the variable region 
are conducted in a two step process in which the variable region of the constant chain undergoes 
gene recombination followed by recombination of the variable region of the light chain (1). Once 
complete the two regions join forming a complex of six hypervariable loops (3 on each chain) 
that extend out from the molecule aiding in the detection and docking of the antigen complexes 
(1). These loops, also known as complementarity determining regions, aid in the specificity of 
the molecule (1).  
B cell Development 
As with all natural processes of such complexity there is room for error. The immune 
system has comprised a series of checks and balances to regulate B cell development, so that 
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cells producing antibodies that are self reactive, and may mount an immune response to one’s 
own cells (autoimmune disease), can be recognized and removed. The elimination of these cells 
is an essential key to regulation of the immune response and is crucial to the host’s survival.  
In order to prevent the onset of an autoimmune disease self reactive cells must be 
removed from the cell repertoire before leaving the bone marrow and entering into the 
circulation. To do so the immune system screens cells within the bone marrow for self reactivity. 
If the B cell shows any form of self reactivity one of two outcomes are used to rectify the 
problem; receptor editing or clonal deletion (2-11).   Receptor editing is a last chance effort 
utilized to save the immature self reactive B cells from cell death (2-5). Receptor editing results 
in a secondary rearrangement of the light chain locus that may help deter self reactivity of the B 
cell’s receptor (13-16). Casellas et al. showed that receptor editing plays a major part in shaping 
the B cell repertoire and takes place during a 2 hour delay during pre B cell development. At 
least 25% of the pre B cell population undergoes editing and express edited versions of 
autoreactive antibodies (16, 17). In other models transgenic mice were knocked in (genetically 
inserted) with autoreactive B cell receptors, providing the potential for secondary rearrangements 
(16, 18, 19). These models showed that autoreactive B cell receptors were edited at a higher rate 
than their harmless counterparts (16, 18, 19). 
Clonal deletion results in B cells being targeted for removal. This process involves a cell 
signaling cascade induced by cell surface receptors that trigger apoptosis (programmed cell 
death) (20-25).  Apoptosis results in the degradation of organelles, and the denaturation of 
proteins, and the digestion of DNA within the cell. 
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Apoptosis  
During lymphocyte development deletion of cells by apoptosis is an important process 
that removes potentially harmful cells produced by improper gene rearrangements. The process 
of apoptosis involves the detachment of a cell from its surrounding environment. All stimulatory 
signals are terminated, and the cell undergoes internal suicide. As the DNA and organelles within 
the cell condense, the mitochondrial induced apoptotic channel becomes more permeable 
resulting in increased levels of cytochrome c leaving the mitochondria (26). This release of 
cytochrome c is considered the full commitment step to apoptosis in many cell types (27-30). 
Cytochrome c has the ability to activate caspase 9, a cysteine protease, which can then activate 
other caspases within the cell including caspase 3 and 7. Each caspase has a unique function in 
apoptosis by carrying out the steps involved in cell death, including degradation of chromosomal 
DNA and proteins. The breakdown of membrane proteins results in increased permeability of the 
cell membrane exposing the cell’s dying state to cells within the surrounding tissue that recruit 
phagocytes that aid in the removal and digestion of the cell fragments via phagocytosis (31).  
 There are many variations of apoptotic induced cell death that depend upon the state of 
the cell and the form of apoptosis initiation. The two main apoptotic pathways are; one, the result 
of the loss of signal transduction required for development (Death by neglect) and two, the result 
of receptor induced signal transduction (Death by instruction) (32). During development, B cells 
receive multiple stimulatory signals that are responsible for differentiation and proliferation of 
the cell. If these signals are not present or the cell cannot receive the signals, the cell will die due 
to neglect. As the B cells undergo gene rearrangements during their development, the cells are 
screened at multiple checkpoints. Though the cells may be healthy, errors within antigen 
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receptors may also cause the initiation of apoptosis through a receptor mediated complex 
(Instruction).  
A well studied model that provides a great example of a receptor mediated death domain 
complex is the Fas (CD95) system, found on cells in the peripheral circulation of mammals, 
which is illustrated in Figure 1.  Fas (CD95), is the key component in this apoptotic process (33). 
The Fas cell receptor (FAS) becomes active when it is bound by Fas ligand (FASL) (33). This 
activation results in the recruitment of the Fas associated death domain (FADD) protein (33). 
The interaction between Fas and FADD forms what is known as a death effector domain (DED) 
which interacts with internal inactive proenzymes known as caspases (34).  Procaspase 8 
interacts directly with the Fas/FADD complex and becomes active Caspase 8 through substrate 
cleavage (34). This triggers a cascade of intracellular events eventually leading to the cleavage 
and condensation of DNA in the nucleus resulting in cell death (33, 35). The Fas receptor is not 
detected in the bone marrow of mammals, thus indicating that there is another molecule involved 
in cell apoptosis there (36). Thus suggesting that there is another mechanism by which clonal 
deletion occurs in both humans and chickens.  
Figure 1: Fas (CD95) Death Receptor System 
 
 
 
 
 
7 
 
Bursa in Chickens – A Model for B Cell Development 
 Studying lymphocyte development in the bone marrow of humans poses a difficult task. 
Multiple blood cell lineages develop in the bone marrow, and there is no clear delineation of a 
specific region where lymphocytes reside. To isolate individual B cells from the meshwork of 
cells poses a highly expensive and very difficult task. Within the bone marrow there is no clear 
delineation of positioning that could provide a timeline for B cell development thus making it 
difficult to isolate cells at certain stages within their development. Another factor contributing to 
the difficulty in using bone marrow as a model for study is the identification of individual B cells 
among millions of other white blood cells and lymphocytes.   
The Bursa of Fabricius, a primary lymphoid organ found in avian species, has become a 
valuable research model to study and understand B cell development.  The bursa in chickens is 
located near the cloaca and orginates as an epithelial bud from the gut lining. The bursa is solely 
devoted to B cell production, thus providing a model to study without interference of other cells 
or tissues. In experiments conducted where chickens were bursectomized at 60 hours of 
embryonic development the animals showed an inability to have either functional or specific 
antibody responses (37-41). DNA analysis of the bursectomized chickens showed Ig light and 
heavy chains with very minimal differences in V-J and V-D-J joints (37-41). The bursectomized 
chickens had very few B cell precursors that differentiated into mature Ig producing cells thus 
the diversity of the B cell receptors was highly restricted (37-41). Collectively this demonstrates 
that the Bursa is critical for the development of B cells and the immune system within avian 
species.  
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During a chicken’s embryonic development, starting at day 8 and continuing up to day 
14, the bursa becomes seeded with B cell precursors (42). Once in the bursa these precursor cells 
begin to proliferate, forming lymphoid follicles, each consisting of approximately 10
5 
lymphocytes that originated from only 2 to 4 precursor cells (43, 44). As these follicles are 
generated only a select few, less than 5%, of the mature B cells exit the bursa to travel into the 
secondary tissues in which they will come into contact with antigens (43). The remaining 95% of 
the cells undergo apoptosis and are removed from the repertoire of cells.  
chB6 & its Role in B Cell Development 
The avian chB6 alloantigen, originally called Bu-1, was defined as a marker of B 
lymphocytes in chickens. Classic experiments by Houssaint showed that chB6 was expressed on 
the earliest identifiable B cell progenitors and continued to be expressed on B cells until their 
terminal differentiation into plasma cells (45, 46, 47). Houssaint also reported expression of 
chB6 on a subset of macrophages in the bursa, liver, and intestine (45, 46, 47).  Subsequent work 
by Funk et al. showed that crosslinking chB6 with an anti-chB6 antibody led to apoptosis in both 
primary B cells and the DT 40 cell line (48).  Tregaskes reported the cloning of cDNAs encoding 
three distinct alleles of chB6; accession numbers X92866 (chB6.1), X92867 (chB6.2), and 
X92865 (chB6.3) (49).  Tregaskes showed that chB6 is a type I transmembrane protein 335 
amino acids in length (49). The 184 amino acid extracellular domain contains six sites for 
potential N-linked glycosylation and a number of conserved cysteine residues (49). The single 
transmembrane region is followed by a 105 amino acid cytoplasmic domain characterized by a 
number of acidic residues and high  proline content (49). Notably, no similarity with known 
proteins was reported.  Each cDNA sequence retained the unique structure of the chB6 protein 
with slight variations within amino acid (AA) residues. Using chB6.1 as the reference sequence 
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chB6.2 has the following amino acids changes: L12 to W12, P47 to L47, N52 to K42, N54 to 
S54, S66 to L66, K111 to E111, I116 to F116, R120 to W120, D183 to G183 (Figure 2). chB6.3 
has the following changes in reference to chB6.1: P47 to L47, N52 to K22, N54 to S54, S66 to 
L66, K111 to E111, K144 to Q144, N147 to Y147, G154 to E154, G172 to V172, E173 to Q173, 
L-238-I (Figure 1). Based on the pattern of amino acids changes Tregaskes et al. concluded that 
the three alleles were equally divergent from one another. Notably all N-linked glycosylation 
sites and cysteine residues are conserved in all three alleles.  They also noted that the 
cytoplasmic domain was highly conserved with only a single isoleucine to leucine change at 
position 238. 
 In 1997 our lab found that ligation of chB6 by an anti-chB6 antibody induced apoptosis, 
suggesting that the molecule had a role in apoptosis (50). In addition, we have shown that the 
chB6 apoptotic pathway can be transferred to mouse cell lines through transfection experiments,  
providing evidence that it is a regulated form of cell death (48, 51). In more recent studies we 
have explored the intracellular events that lead up to cell death after crosslinking of the chB6 
death receptor induced by ligation via anti-chB6 antibodies. In these studies both caspase 3 and 8 
become activated once the receptor is ligated (52). These caspase molecules are part of the 
intracellular machinery that degrades the cellular components during apoptosis (53). 
Collectively, these studies indicate that chB6 causes apoptosis via a mechanism similar to that in 
other death receptor systems, such as Fas (CD95).  
EST Database  
 Expressed sequence tag (EST) databases contain sequences of automated single stranded 
reads of DNA obtained from cDNA clones (54). The process by which these sequences are 
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obtained is different from other genomic databases and stems from years of genomic research. 
EST databases are compiled of very limited information, whereas genomic databases are 
compiled of entire genomes, and redundant information. For example when looking at a genomic 
database, the sequences utilized are entire gene sequences (DNA) and include more information 
than a short sequence read you would find in an EST database. When cells express a particular 
gene they begin by transcribing the DNA into mRNA which is then later translated into a 
protein. At any given time within a cell the RNA expressed is a sampling of the genes expressed 
by that cell. By taking a sampling of the RNA and converting it into complementary copies of 
DNA (cDNA) researchers can compile profiles of the DNA within the cells under specific 
conditions or stages. The cDNA can then be ligated into plasmids which are essentially small 
circular pieces of DNA that can be grown in bacteria. Each specific plasmid contains one of 
cDNA from the source cell that can be transformed into a bacterium to reproduce pure copies of 
the cDNA. Collectively these cDNA sequences comprise a library of expressed genes from a 
particular cell type. The cloned sequences can then be entered into a computer database. 
However the automated sequencing methods used to derive these cDNAs are known to contain 
errors. Thus, any cDNA sequences used for genetic information must be obtained and 
resequenced to ensure the information provided in the database is correct. 
Since three alleles of chB6 were identified by Tregaskes (49), we set out to test the 
hypothesis that there were other, as yet uncharacterized alleles.  By searching the EST databases 
using the known chB6 alleles (chB6.1, chB6.2, and chB6.3) we expected to find other alleles of 
chB6. The conservation of both the structural and functional components between these new 
alleles could provide new insight into regions of the molecule that are critical for the function of 
the molecule as an apoptotic cell receptor. Furthermore, we predicted that we would be able to 
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clone chB6 homologue(s) in related bird species. Comparison between avian species could also 
provide information on the degree of conservation of this molecule.  
 
Methods and Materials 
Database Searches 
Nucleotide sequences of chB6 (Accession numbers X92865, X92866, X92867) were 
used to search the National Center for Biotechnology Information’s (NCBI) Expressed Sequence 
Tag database nucleotide blast (nblast) search engine. EST retrievals were translated from 
nucleotide sequence to amino acid sequence using the Expert Protein Analysis System (ExPASy) 
provided by the Swiss Institute of Bioinformatics.  ESTs identified in this search were 
individually analyzed by alignment to identify both amino acid similarities with chB6.1 and the 
potential novel alleles. Alignment figures were produced using the multiple sequence alignment 
program, MAFFT version 6. Alignments with 100% identity to known chB6 were excluded from 
further analysis. EST clones showing greater than 50% identity to chB6 were analyzed for 
possible novel allele identification.  
EST Clone Preparation 
 EST clone AM067700 was obtained from pooled chicken lymphoid tissues (Bursa, 
spleen, and Peyers patch of a Strain Lohman Brown layer/Ross 308 broiler cross) at the ARK-
Genomics Center for Functional Genomics in Farm Animals at the Roslin Institute, Midlothian, 
U.K. Samples were provided as LB agar stabs containing 50 µg/ml of ampicillin. The stab was 
transferred to liquid culture in LB broth containing 50 µg/ml ampicillin then grown overnight at 
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37°C. The culture was then streaked out onto LB agar containing ampicillin (25 and 50 µl 
aliquots). Single colonies were picked and cultured in liquid broth followed by miniprep and 
sequencing. 
 EST clones BQ038848, CB016728, CB017782 were obtained from normalized chicken 
lymphoid tissue (thymus, bursa, spleen, PBL, and bone marrow, strain of bird not indicated) at 
the Delaware Institute of Biotechnology in Newark, Delaware and provided as bacterial cultures 
in LB broth with ampicillin and 15% glycerol. Clones were streaked onto LB and Ampicillin 
plates at 15, 30, and 45 µl aliquots and then incubated over night at 37°C. Single colonies were 
picked and cultured in liquid broth followed by miniprep and sequencing. 
 EST clone AJ456867 was obtained from a CB strain inbred chicken from the Jean 
Buerstedde lab, at the Heinrich-Pette-Institute in Hamburg, Germany and provided as a purified 
cDNA culture.  
 
Plasmid Isolation 
Plasmids were isolated from overnight culture following the QIAprep Spin protocol 
precisely (www.qiagen.com). An overnight culture (3 mL) was spun in a centrifuge to pellet 
bacteria. The cells were lysed and DNA was eluted and purified using affinity columns.  
Sequencing 
Plasmids isolated were sent to Davis Sequencing, L.C. in Davis, California for 
sequencing analysis. Once sequencing was completed chromatograms were visually analyzed for 
proper base reads. Each nucleotide sequence was then translated with Expasy and aligned with 
chB6.1, chB6.2, and chB6.3 via MAFFT. 
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RT-PCR of Turkey cDNA  
chB6.1 primers chB6F 5’-ATGGATTTCAACTCTCCTTTTATTC-3’ and chB6R 5’- 
ATGGATTTCAACTCTCCTTTTATTC -3’ that were designed by Kent Reed at the University 
of Minnesota in St. Paul,  MN were used to amplify the chB6.1 homologue in turkey cDNA via 
RT-PCR.  
RT-PCR protocol – Synthesis of First- Strand cDNA 
The synthesis of the first strand cDNA was conducted according to the Stratagene 
AccuScript RT-PCR protocol (stratagene.com/manuals/200820.pdf). The cDNA synthesis 
reaction mixture used for first strand synthesis was composed of 16.5 µl of RNase free H2O, 2 µl 
of 10x AccuScript RT buffer , 0.8 µl of dNTP mix, and 0.2 µl of concentrated mRNA ( 
approximately 200ng) from turkey lymphoid tissue (Nicholas line). The reaction mixture was 
then incubated for five minutes at 65°C.  This was then followed by a cool down at room 
temperature for five minutes. 1 µl of mM DTT was added to the mixture along with 1.0 µl of 
AccuScript RT. The reaction was then placed in a controlled thermal block at 42°C for thirty 
minutes and finally chilled on ice for use in later PCR amplifications.  
Amplifying the cDNA template 
To amplify the desired chB6.1 cDNA the following components were mixed together 
using a sterile thin walled PCR tube: 40 µl of RNase free H2O, 5 µl of 10x PCR buffer, 1 µl of 
dNTP mix (2 mM), 1 µl of chB6F upstream primer (100 ng/µl), 1 µl of chB6R downstream 
primer (100 ng/µl), 1 µl of first strand cDNA reaction, and 1 µl of PfuUltra HF DNA 
polymerase. The amplification profile was: first cycle at 95°C for one minute; followed by forty 
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cycles at 95°C for thirty seconds, 57°C for thirty seconds, and 68°C for three minutes, and one 
finish cycle at 68°C for ten minutes.  
PCR Amplification and Transformation- Strata Clone Blunt PCR Cloning Kit 
Once a positive cDNA amplification was verified using an agarose gel the PCR product 
was cloned using the Strata Clone Blunt PCR Cloning Kit 
(www.genomics.agilent.com/files/Manual/240207.pdf). Agarose plates treated with 40 µl of 2% 
X-gal and IPTG were used to culture the bacterial colonies. Aliquots (5 and 100 µl) of the 
transformation mixture were incubated overnight at 37°C.  White colonies showing successful 
transformations were utilized for further plasmid DNA analysis (55). 
 
Results 
 
Novel Allele Analysis 
Based on the genetic diversity seen in Tregaskes cloning work, we hypothesized that 
there might be other alleles of chB6 in chicken populations. From a preliminary EST database 
search using each of the three known alleles as the search criteria, a pool of 17 EST hits were 
retrieved. After an alignment analysis of each individual hit to the known alleles, candidates 
having an identical match to chB6.1, chB6.2, and chB6.3 were discarded. From the pool of 17 
hits, a total of 4 putative novel alleles were identified. Given the errors that might be included in 
EST reports, candidates with possible novel amino acid changes were acquired and resequenced 
to confirm base pair changes. For all of the alleles an alignment diagram was composed 
illustrating the various amino acids that are either similar or different in each of the alleles 
(Figure 2). Table 1 was composed to show the location of each of the amino acids, and whether 
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or not the changes seen were conservative or non conservative. Use both Figure 2 and Table I as 
an illustration for the results below. 
EST clone BQ038848 (Delaware Institute of Biotechnology) was found to be a truncated 
cDNA sequence until residue 54 where it had a change from N54 to S54. The overall sequence 
of BQ038848 is similar to chB6.2 with the following key exceptions; R120, Q144, Y147, E154, 
A169, R186 and I238 are unlike chB6.2. In fact the arginine at position 186 and the alanine at 
position 169 are unique among the three previously reported alleles of chB6.  With the exception 
of these two unique substitutions, the pattern of changes seen in BQ038848 appears to be 
intermediate between the previously described alleles. For instance, R120, Q144, Y147, E154 
and I238 do not appear in chB6.2 but are found in chB6.3. In all of these instances amino acids 
encoded are found in at least one of the other alleles, making it unlikely that the change is due to 
an error introduced by reverse transcription, PCR, or any subsequent manipulation of the cDNA.  
Rather, it suggests that the alleles are related with a preferred pattern of substitutions allowed at a 
particular place in the amino acid chain.  
AJ456867 (Heinrich-Pette-Institute) is a full length cDNA with striking sequence 
similarity to chB6.2. The only difference between AJ456867 and chB6.2 is a single substitution 
of L12 for W12 in the signal sequence, making this cDNA unique. 
EST clone CB016728 (Delaware Institute of Biotechnology) is very similar to BQ038848 
however the cDNA sequence is not truncated and is full length. The full length sequence has 
similar substitutions to that of both chB6.2 and chB6.3. Within the first 115 amino acids 
CB016728 has the exact same substitution as chB6.2 and chB6.3, minus the substitution in 
chB6.2 at position 12. At amino acid 116 it is similar to chB6.2 yet loses its similarity to chB6.2 
at amino acid 120 and retains its resemblance to chB6.3. The sequence then retains this similarity 
16 
 
for the next 59 amino acids until it has a unique change at position 169 from T to A. At amino 
acid 172 and 173 it shows a similar resemblance to ch6.2 once again until position 186 where it 
has a unique substitution of W to R. The latter half of the sequence then retains chB6.3 
composition with one highly unique change at amino acid 289 from S to L. 
CB017782 (Delaware Institute of Biotechnology) has an amino acid sequence that is very 
similar to each of the other alleles (chB6.2, chB6.3, BQ038848, AJ456867, and CB016728) 
within the first 115 amino acids. At position 116 it begins to look more like chB6.1 and chB6.3 
until position 134 where it has a unique substitution from D to Y. For the next 104 amino acids 
the sequence is identical to chB6.1 until it switches back to sharing a similar substitution to 
chB6.3 at amino acid 238. The cytoplasmic portion of the sequence is identical as seen with all 
the alleles except for one highly distinctive substitution of Q at amino acid 286, making this 
cDNA quite different from the others.  
In each of the novel alleles there are various amino acid changes that characterize 
differences within the sequence and the changes appear to cluster in particular stretches of the 
primary sequence. However, some regions of sequence are absolutely conserved, suggesting a 
functional importance. The signal sequence, with one exception (amino acid 12 in chB6.2), and 
transmembrane portions of the molecule are 100% conserved. In each of the alleles the 6 putative 
N-glycosylation sites and all cysteine residues are 100% conserved suggesting that disulfide 
bonding and glycosylation are critical to the in vivo function of chB6. About 50% of the 
molecular weight of chB6 on the B cell surface is accounted for by glycosylation (48). The 
majority of the amino acid changes occur within the extracellular domain. The cytoplasmic 
region of each of the alleles is also highly conserved thus suggesting the functional importance 
of this portion of the molecule within the cell.  
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Figure 2. Alignment of Novel chB6 Alleles. CLUSTAL format alignment by MAFFT (v6.708b). 
X92866 (chB6.1), X92867 (chB6.2), and X92865 (chB6.3) are the three known alleles published by 
Tregaskes et al. 1996. BQ038848, AJ456867, CB016728, CB017782, and AM077700 are the novel 
alleles gathered and sequenced from the EST database searches. X92866 is the reference sequence for the 
results. N-linked glycosylation sites are shown in red font and the cysteine residues are double underlined 
in red. Each domain of the protein is characterized. Each set row is a total of 60 amino acids long. 
Polymorphic sites are highlighted in yellow. 
 
  0                    60 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
X92867          MDFNSPFILQCWLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
X92865          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
BQ038848        -----------------------------------------------------SNCSTAV 
AJ456867        MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
CB016728        MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
CB017782        MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
               │        Signal       │         Extracellular     
         
 
              61                                                          120    
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
X92867          VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAW 
X92865          VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPIIDAR 
BQ038848        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAR 
AJ456867        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAW 
CB016728        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAR 
CB017782        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
            Extracellular 
               
 
             121                                                          180 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
X92867          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
X92865          CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKTVPVQFVCKVTY 
BQ038848        CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKAVPGEFVCKVTY 
AJ456867        CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
CB016728        CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKAVPGEFVCKVTY 
CB017782        CFPNGTADLTCNVYSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
                                       Extracellular 
 
 
             181                                                          240 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
X92867          NNGFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
X92865          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
BQ038848        NNGFVRTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
AJ456867        NNGFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
CB016728        NNGFVRTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
CB017782        NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
                                        │    Transmembrane        │ 
              
 
             241                                                          300 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
X92867          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
X92865          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
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BQ038848        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
AJ456867        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
CB016728        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDLGIVPQPMVEEN 
CB017782        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAAQPDSGIVPQPMVEEN 
                                        Cytoplasmic 
      
 
             331                                   335 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
X92867          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
X92865          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
BQ038848        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
AJ456867        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
CB016728        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
CB017782        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                           Cytoplasmic             │ 
 
Turkey Sequence Analysis 
Given the apparent allelic diversity within chickens we attempted to clone a chB6 
homologue from a related galliform, the turkey. Turkey bursal RNA was subjected to RT-PCR 
with chB6 specific primers and the PCR product was cloned using the Strataclone Blunt PCR 
cloning kit. Twelve different clones were sequenced and the consensus AA sequence is presented 
(Figure 3).  The Turkey cDNA aligned with X92866, X92867, and X92865 shows a high level of 
conservation between each of the sequences. X92866, X92867, and X92865 are each 335 amino 
acids long however the Turkey sequence is 2 amino acids shorter (333). The CLUSTAL format 
alignment by MAFFT inserted two spaces at amino acids 24 and 25 to align the Turkey sequence 
with the chicken sequences.  
The turkey sequence retains a number of the key features seen in the chB6 molecule with 
very minimal changes, including the N-linked glycosylation sites and cysteine residues. The 
majority of the amino acid changes occur within the extracellular portion of the sequence (Figure 
3 and Table I). Both the signal and transmembrane sequence are highly conserved. The turkey 
sequence has 2 unique amino acid changes at the end of the signal sequence of D20 to A20, and 
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G21 to D21. The transmembrane sequence is 100% conserved. Out of the 15 cysteine residues 
14 of them are conserved with one change of C76 to R76. Of the 5 N-linked glycosylation sites, 
4 are identical. The fifth site, at positions 138-140 is shifted by two amino acids. A very 
distinctive change occurs between amino acids 136-140. The N-linked glycosylation site in 
X92866, X92867, and X92865 is N138/M139/T140. In the turkey sequence amino acid N138 is 
changed to S138; thus disrupting that bonding site. However, the two upstream amino acids are 
N136 and E137, thus forming a new N-linked glycosylation site of N136/E137/S138. Though the 
amino acid makeup and position shifted is by 2 residues, the structural integrity of the molecule 
is still intact. The shift may be due to the fact that the turkey sequence is 2 amino acids shorter. 
The cytoplasmic domain is also highly conserved, however the substitution of two residues with 
acidic residues further heightens that charge normally found on chB6. Another change is a 
conservative substitution of D243 with E243, preserving the consensus CK2 phosphorylation 
site.  
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Figure 3. Alignment of Turkey chB6 homolog. Using CLUSTAL format alignment by MAFFT 
(v6.713b) X92866 (chB6.1), X92867 (chB6.2), and X92865 (chB6.3) were used as the reference 
sequences for alignment of the Turkey cDNA. N-linked glycosylation sites are shown in red font 
and the cysteine residues are double underlined in red. Each domain of the protein is indicated. 
 
               0                                                           60 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
X92867          MDFNSPFILQCWLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
X92865          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
Turkey          MDFNSPFILQCLLVITTVTADST--IGVFSGSSAKFPVEVESFRNVQKMIWNNNNCSTTM 
               │        Signal       │         Extracellular     
 
               61                                                         120 
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
X92867          VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAW 
X92865          VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPIIDAR 
Turkey          KNDILLAKCHSSSERRLELDNGSLVLRSVEKEDEGKYQFFFNDTEVLYTLKVFEPIIDAR 
                                        Extracellular 
   
              121                                                         180 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
X92867          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
X92865          CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKTVPVQFVCKVTY 
Turkey          CFPNGTADLTCDMDSNESMTFEWLLNNSRLNAHEACIKDGGKKVRLEKSVPGEFVCKVKH 
                                       Extracellular 
 
              181                                                         240 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
X92867          NNGFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
X92865          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
Turkey          DHGSLRTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
                                        │    Transmembrane        │ 
 
              241                                                         300 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
X92867          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
X92865          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
Turkey          PSEEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIDCPPMPDAARTDSGTEPQPMVEEN 
                                       Cytoplasmic 
 
              301                                  333 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
X92867          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
X92865          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
Turkey          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                            Cytoplasmic            │ 
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Table I. Summary of Amino Acid Changes among chB6 Molecules. The clones are labeled by 
their accession numbers. Along the top are the domains of the chB6 sequence. Each of the clones 
are compared to the chB6.1 sequence and the amino acids that are different are labeled below. 
For example clone # X92867 has a tryptophan in place of a leucine at amino acid position 12 in 
chB6.1 (L-12-W). Any changes highlighted are non conservative meaning they are either going 
from polar to non polar (vice versa), charge changes (+ to -, or – to +), or both depending on the 
amino acid composition. 
Clone 
Accession # 
Signal  Extracellular Transmembrane  Cytoplasmic 
X92867 
(chB6.2) 
L-12-W  P-47-L, N-52-K, N-54-S, S-66-
L,  K-111-E , I-116- F, R-120-
W, D-183-G 
Conserved Conserved 
X92865 
(chB6.3) 
Conserved P-47-L, N-52-K, N-54-S, S-66-
L, K-111-E, K-144-Q, N-147-
Y, G-154-E, G-172-V, E-173-Q 
Conserved L-238-I 
BQ038848 Truncated N-54-S, S-66-L,  K-111-E, I-
116- F, K-144-Q, N-147-Y, G-
154-E, T-169-A, D-183-G, W-
186-R  
Conserved L-238-I 
AJ456867 Conserved P-47-L, N-52-K, N-54-S, S-66-
L,  K-111-E , I-116- F, R-120-
W, D-183-G 
Conserved Conserved 
CB016728 Conserved P-47-L, N-52-K, N-54-S, S-66-
L,  K-111-E, I-116- F, K-144-
Q, N-147-Y, G-154-E, T-169-
A, D-183-G, W-186-R 
Conserved L-238-I,  S-
289-L  
CB017782 Conserved P-47-L, N-52-K, N-54-S, S-66-
L,  K-111-E, D-134-Y 
Conserved L-238-I, R-
286-Q 
 
Turkey 
D-20-A, 
G-21-D 
A-23-T, A-28-V, L-29-F, L-38-
V, G-39-E, N-42-S, Q-44-R, P-
47-Q, S-50-Q, S-53-I, A-59-T, 
V-60-M, V-61-K, D-62-N, T-
64-I, S-66-L, E-68-K, P-71-S, 
K-74-E, C-76-R, K-78-E, E-80-
D, R-88-S, N-96-K, E-98-K, K-
105-E, F-108-Y, N-132 -D, V-
Conserved D-243-E, A-
277-D, P-
287-T, I-291-
T, and V-
292-E 
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133-M, N-138-S, K-144-L, W-
149-R, P-150-L, N-153-H, G-
154-E, V-157-I, T-169-S, T-
179-K, Y-180-H, N-181-D, N-
182-H, D-183-G, F-184-S, V-
184-L 
 
Discussion 
The chB6 alloantigen has been used as a cell marker throughout various stages of B cell 
development (45, 46, 47). Prior research has shown that chB6 acts as an apoptotic cell receptor 
that can also retain this function when transfected into mammalian cell lines (48, 50). However, 
there has been no success in finding a homologue to the chB6 receptor in mammalian cell lines. 
Understanding more about the genetic diversity of the chB6 cell receptor in birds may help 
categorize the functional domains of the molecule and may aid in the search for a mammalian 
counterpart to the molecule. Utilizing the three published alleles chB6.1, chB6.2, and chB6.3 we 
were able to identify four putative novel alleles, and an orthologous sequence with high sequence 
similarity to that of chB6 in turkeys. Our results further characterize the functionally critical 
domains of the molecule, and regions where substitutions of amino acids are tolerated without 
presumably interrupting the function of the molecule.  
N-linked Glycosylation Sites 
      N-linked protein glycosylation is most commonly found in eukaryotic cells and has an 
important role in the modification of secretory and membrane proteins (56). N-linked 
glycolsylations overall course of action is associated with protein translocation and folding (58). 
In identifying alleles of a gene N-linked glycosylation sites would be presumably conserved in 
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order to retain folding patterns and binding domains. The typical amino acid sequence of N-
linked glycosylation sites occur in three amino acid spans, N-X-S or N-X-T, where X can be any 
amino acid except for proline. In chB6.1 there are 5 N-linked glycosylation sites that are 
highlighted in red (Figure 2).  All of these sites are found in the extracellular domain of the 
molecule. In each of the other alleles, including the four novel alleles, the location of the sites are 
entirely conserved with only one amino acid variation at AA 147 from N to Y in alleles chB6.3, 
CB016728, and BQ03884. One would allow for variation at this amino acid position due to the 
substitution occurring at the X position where you can have any amino acid except for proline. In 
the turkey allele the N-linked glycosylation sites are also nearly identical to that of chB6 alleles, 
except for one site that is shifted two amino acids from NMT and position 138 to NES at 136. 
Overall the results show that the N-linked glycosylation sites are conserved and thus are 
important to the structure of the molecule. Since about half of the observed molecular weight of 
chB6 on the cell surface is accounted for by glycosylation it would seem likely that the 
carbohydrate moieties are critical to its function (49). 
Cysteine Residues 
 Cysteine residues within protein structures contain thiol groups that are known to be 
nucleophilic and thus are easily oxidized (57). Cysteine plays an important role in the structural 
bonding patterns of proteins (57). The reactive thiol groups of the molecule form the disulfide 
bridges that are critical to the three dimensional folding of the protein (57). In chB6.1 there are 
14 cysteine residues that are found in all domains of the molecule. The results show that all 14 of 
the cysteine residues are 100% conserved in all of the alleles of chicken which helps to further 
characterize the vital role they have in the structure of the molecule. In the turkey allele, 13 of 
the 14 cysteine residues are conserved (Figure 2). The cysteine residue at position 76 is 
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substituted by an arginine (R). This substitution is found in the extracellular region where we see 
the majority of the amino acid substitutions occur, and again may also be due to the fact that the 
sequence is two amino acids shorter. The loss of these two amino acids may allow for slight 
variations in the patterns we see in each of the highly conserved alleles.  
chB6 and the Novel Alleles 
 Based on the results presented (Figure 2 and Table I) each of the four putative novel 
alleles are quite similar to that of the originally published chB6.1, chB6.2, and chB6.3. Overall 
the majority of the substitutions in all of the alleles occur in the extracellular region of the 
molecule. In each of the alleles most of the substitutions are similar to that of another allele 
which suggests that the substitutions seen are tolerated without changing any function of the 
molecule. The most highly conserved regions between each of the alleles are the regions with 
defined functions including the signal sequence, transmembrane region, the cytoplasmic tail, and 
about five stretches of the extracellular domain. In the signal sequence there is only one 
substitution out of all the alleles seen in chB6.2 at amino acid 12 from L to W. The 
transmembrane region is 100% conserved even in the turkey homologue.  
The cytoplasmic tail is also highly conserved with a common amino acid change seen in 
chB6.2 and three of the novel alleles BQ038848, CB016728, and CB017782 of L to I at amino 
acid 238. The other two substitutions are unique to two of the novel alleles. CB016728 has a 
unique change at residue 289 switching from S to L and CB017782 has a unique change at 
position 286 of R to Q. The turkey homologue shows a similar strong conservation of this amino 
acid sequence, thus further providing evidence of the functional importance of the cytoplasmic 
tail. This would be expected if chB6 had a critical association with cytoplasmic proteins. We 
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have found that the stretch of 15 amino acids within the cytoplasmic domain is essential for 
transduction of a death signal (Funk, unpublished observations) and that sequence is conserved 
in turkey, as is the CK2 phosphorylation site. However, the conservation beyond even this 
suggests that other parts of the cytoplasmic domain have critical functions necessitating 
conservation, perhaps regulatory functions. Furthermore, the nearly absolute conservation of the 
transmembrane and cytoplasmic domain of chB6 provide a target for experiments to clone chB6 
homologues from more distantly related aves and perhaps even reptilia.  
Within the extracellular domain we find some large blocks of conserved sequence and 
defined areas where limited changes are allowed. For instance, the first 23 amino acids after the 
signal sequence are conserved in all chicken alleles. Likewise the sequence from amino acid 66 
to 111, from 121 to 144, and 187 to 204 are completely conserved in all chicken alleles with the 
single exception of a D to Y change at position 134 of CB017782. This would suggest that large 
portions of sequence here are functionally relevant. As a membrane protein it is reasonable to 
postulate that chB6 binds an extracellular ligand. If so, this conservation of the potential binding 
site would be necessary. For instance, in the region from position 66 to 111 there are a number of 
amino acid changes but the individual changes are most often substituting one charged amino 
acid for another, or swapping charged and polar amino acids. Specifically, an E to K change at 
position 66 in the turkey followed by K to E changes at position 72 and 76, an E to D at 78, E to 
Q at position 97, and another K to E at position 104. If these regions were to be exposed to an 
aqueous environment on the exterior of the chB6 molecule such changes would be fairly 
conservative. 
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Future Research 
  The results presented here provide evidence for an additional four alleles of chB6 in 
chickens and a homolog in turkeys. Previous attempts to clone a chB6 homolog in mammals 
have been unsuccessful. Likewise, database searches for a chB6 homolog have been fruitless. 
Nevertheless, introduction of cDNA encoding chB6 into mammalian cells can reconstitute death 
signaling identical to that seen in chicken cells (48, 52), indicating that chB6 engages a death 
signaling pathway conserved since the divergence of aves and mammals roughly 300 million 
years ago.  This is a fundamental puzzle, if chB6 is a unique avian gene why would it still 
engage this conserved pathway? Given that genomic studies are uncovering deep similarities 
among even distantly related species, is it reasonable to conclude that chB6 is in fact unique to 
Aves? 
Death domains and death receptors have been difficult to define. Nevertheless death 
domain containing proteins have been found in many species and evidence indicates that death 
receptors are in fact ancient proteins that predate the emergence of vertebrates (58). Furthermore, 
there is evidence for divergence and functional specialization of death receptors (58). In order to 
understand the place of chB6 among death receptors, we first need to understand the divergence 
of chB6 within birds.  The work here is a first step towards that understanding. 
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Appendix 
Figure 1: chB6.1, chB6.2, chB6.3 
CLUSTAL format alignment by MAFFT (v6.707b) 
 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
X92867          MDFNSPFILQCWLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
X92865          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
                *********** ******************************:*** ****:*.****** 
 
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
X92867          VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAW 
X92865          VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPIIDAR 
                ***** ********************************************:****:***  
 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
X92867          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
X92865          CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKTVPVQFVCKVTY 
                ***********************:** ****** ***************** :******* 
 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
X92867          NNGFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
X92865          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
                **.******************************************************:** 
 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
X92867          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
X92865          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
                ************************************************************ 
 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
X92867          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
X92865          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                *********************************** 
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For the following alignments chB6.1 (X92866) was used as the reference for 
comparison 
CLUSTAL format alignment by MAFFT (v6.707b) 
 
 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
BQ038848        ------------------------------------------------------NCSTAV 
                                                                      ****** 
 
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
BQ038848        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAR 
                ***** ********************************************:****:**** 
 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
BQ038848        CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKAVPGEFVCKVTY 
                ***********************:** ****** **************:*********** 
 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
BQ038848        NNGFVRTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
                **.** ***************************************************:** 
 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
BQ038848        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
                ************************************************************ 
 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
BQ038848        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                *********************************** 
 
 
CLUSTAL format alignment by MAFFT (v6.707b) 
 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
AJ456867        MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
                ******************************************:*** ****:*.****** 
 
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
AJ456867        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAW 
                ***** ********************************************:****:***  
 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
AJ456867        CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
                ************************************************************ 
 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
AJ456867        NNGFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
                **.********************************************************* 
 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
AJ456867        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
                ************************************************************ 
 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
AJ456867        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                *********************************** 
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CLUSTAL format alignment by MAFFT (v6.707b) 
 
 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
CB016728        MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
                ******************************************:*** ****:*.****** 
 
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
CB016728        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLEVFEPFIDAR 
                ***** ********************************************:****:**** 
 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
CB016728        CFPNGTADLTCNVDSNENMTFEWQLNYSWPNANEACVKDGGKKVRLEKAVPGEFVCKVTY 
                ***********************:** ****** **************:*********** 
 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
CB016728        NNGFVRTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
                **.** ***************************************************:** 
 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
CB016728        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDLGIVPQPMVEEN 
                ************************************************ *********** 
 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
CB016728        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                *********************************** 
 
 
CLUSTAL format alignment by MAFFT (v6.707b) 
 
 
 
X92866          MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENFQNVPKMSWNNNNCSTAV 
CB017782        MDFNSPFILQCLLVITTVTDGSATMIGALSGSSAKFPLGVENLQNVLKMSWKNSNCSTAV 
                ******************************************:*** ****:*.****** 
 
X92866          VDDTLSAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
CB017782        VDDTLLAECHPSSKRCLKLENGSLVLRRVEKEDEGNYEFFFNDTKVLFTLKVFEPIIDAR 
                ***** ****************************************************** 
 
X92866          CFPNGTADLTCNVDSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
CB017782        CFPNGTADLTCNVYSNENMTFEWKLNNSWPNANGACVKDGGKKVRLEKTVPGEFVCKVTY 
                ************* ********************************************** 
 
X92866          NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPV 
CB017782        NNDFVWTRPIVLSCSYGDLLQYPWFIYILAGCAGAAAILVAVVSSLICCCMRRKHKFIPV 
                *********************************************************:** 
 
X92866          PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAARPDSGIVPQPMVEEN 
CB017782        PSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDAAQPDSGIVPQPMVEEN 
                *********************************************:************** 
 
X92866          FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
CB017782        FPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
                *********************************** 
                                                    
